Windtreetx

Windtree CEO Jed Latkin comments on the Company's common stock purchase agreement to establish an equity line of credit and bolster its BNB cryptocurrency treasury strategy. Learn more: bit.ly/4meJ0nm $WINT

Establishing the ELOC reflects Windtree’s strategy to diversify its assets & leverage the potential of blockchain-based digital currencies. We remain committed to prudent financial management while exploring innovative avenues to drive value. bit.ly/4meJ0nm $WINT

This partnership positions Windtree to leverage Kraken's industry-leading security, liquidity, and expertise in digital asset management to support its pioneering BNB-focused treasury strategy, encompassing custody, security, and yield generation. bit.ly/4nWQIEl $WINT

Windtree, the first NASDAQ-listed company offering pure play direct exposure to the BNB token, the fifth-largest blockchain by market capitalization (over $100B), expects the collaboration with Kraken to enhance its ability to provide secure access. bit.ly/4nWQIEl $WINT

"We are excited to partner with Kraken, a trusted leader in the cryptocurrency industry, to support our groundbreaking BNB strategy," said Jed Latkin, Chief Executive Officer of Windtree. "Kraken's expertise and secure platform will strengthen our ability."…

Windtree announced a strategic partnership with Kraken, a leading global cryptocurrency platform, to provide custody, trading, and over-the-counter (OTC) services for Windtree's BNB Crypto Treasury Strategy. bit.ly/4nWQIEl $WINT

Jed Latkin, CEO of Windtree, comments on the Company's potential BNB crypto treasury strategy launch with Build and Build Corp. Discover more: bit.ly/3IxV5W3 $WINT

Subject to shareholder approval & the satisfaction of other closing conditions, $WINT will become the first NASDAQ-listed company offering direct exposure to the BNB token, the fifth-largest blockchain by market capitalization (over $95 billion). bit.ly/3IxV5W3

Jed Latkin, CEO of Windtree, comments on the issuance of a U.S. patent for istaroxime, covering its potential use in treating acute heart failure. Discover more: bit.ly/3TGeoip $WINT

$WINT announced that the United States Patent and Trademark Office has issued an istaroxime patent for the United States - application number 18/150,870 directed to “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.” bit.ly/3TGeoip

Windtree believes that this SCAI stage C study will be valuable for Phase 3 readiness of istaroxime in cardiogenic shock because these patients will be an important population for the target indication in the Phase 3 study. bit.ly/46lvnhf $WINT

Windtree CEO Jed Latkin comments on the Company's Phase 2 study of istaroxime for cardiogenic shock, which has successfully hit its enrollment target for the planned interim analysis. Learn more: bit.ly/46lvnhf $WINT

The SEISMiC C interim analysis will provide a preliminary assessment of istaroxime safety in treating more severe cardiogenic shock patients who may be receiving standard of care with inotropes and vasopressors. bit.ly/46lvnhf $WINT

Windtree is pleased to announce that the Company has reached the planned enrollment of 20 patients for the interim analysis in its istaroxime Phase 2 SEISMiC C study in SCAI Stage C cardiogenic shock patients. For details, please visit: bit.ly/44pz5nn $WINT

Windtree CEO Jed Latkin comments on the Company’s new agreement with an outside U.S. manufacturer to produce @Evofem’s hormone-free contraceptive, PHEXXI, at a significantly reduced cost compared to current production levels. Learn more: bit.ly/4et7Zkc $WINT

Windtree expects the recent arrangement will generate revenue for Windtree while reducing @Evofem’s cost to manufacture the PHEXXI by more than 50% by year end 2026. bit.ly/4et7Zkc $WINT